Instruction for use: Norethisterone (Norethisteronum)

Pharmacological group

Estrogens, gestagens; Their homologues and antagonists

Nosological classification (ICD-10)

D26 Other benign neoplasms of the uterus

Fibromyoma of the uterus, Myoma, Uterine fibroids, Fibromyoma, Myoma of the uterus, Fibrrios, Meigs syndrome, Tumors of the uterus

N64.4 Mastodinia

Mastalgia, Soreness of the mammary glands, Cooper's disease

N64.9 Mammary disease, unspecified

Mastopathy, Neoplastic processes in the mammary gland

N80 Endometriosis

Endometrioid endometriosis

N80.0 Endometriosis of the uterus

Adenomyosis, Endometrioid endometriosis

N85.0 Endometrial glandular hyperplasia

Hyperplastic processes of the endometrium, Cystic glandular hyperplasia of the endometrium

N93.9 Abnormal uterine and vaginal bleeding, unspecified

Uterine bleeding, Dysfunctional uterine bleeding, Uterine bleeding dysfunctional

N94.3 Premenstrual tension syndrome

Pronounced premenstrual syndrome, Menstrual psychosomatic disorder, Menstrual syndrome, Premenstrual tension, Premenstrual status, Premenstrual period, Premenstrual syndrome, Menstruation syndrome

N94.4 Primary dysmenorrhea

Primary functional dysmenorrhea, Pain in primary dysmenorrhea, Primary algodismenorea, Menstrual cramps

N94.5 Secondary dysmenorrhea

Dysmenorrhea secondary acquired, Menstrual cramps, Ovarian depletion syndrome

N94.6 Dysmenorrhea Unspecified

Pain during menstruation, Functional disorders of the menstrual cycle, Menstrual cramps, Emmeniopathy, Pain during menstruation, Painful menstrual irregularities, algomenorrhea, algomenoreya, Pain smooth muscle spasm, Pain spasm of smooth muscles (renal and biliary colic, intestinal spasms, dysmenorrhea), Pain spasm of smooth muscles of internal organs (kidney and biliary colic, intestinal spasms, dysmenorrhea), Disalgomenoreya, dysmenorrhea, Dysmenorrhea (essential) (Exfoliative), menstrual disorder, menstruation painful, metrorrhagia, Violation of the menstrual cycle, Menstrual irregularities, Prolaktinzavisimoe menstrual disorders, Prolaktinzavisimoe menstrual dysfunction, Pain spasm of smooth muscles of internal organs, Spasmodic dysmenorrhea, Primary disalgomenoreya

N95.9 Menopausal and perimenopausal disorders, unspecified

Postmenopause, Atrophy of the vulva, Climacteric syndrome, Postmenopausal period, Premenopausal period, Menopausal Symptom

N97 Female infertility

Female infertility in anovulation, Hyperprolactinemic infertility, Hyperprolactinaemia with infertility, Endocrine infertility, Infertility due to hypothalamic-pituitary dysfunction, Infertility infertility, Infertility, Infertility on the background of hyperprolactinaemia, Functional infertility, Marriage is infertile, Infertility of ovarian genesis, Stimulation of the growth of a single follicle

O26.2 Medical care for a woman with habitual miscarriage

Miscarriage habitual, Unintention of pregnancy, Habitual miscarriage of pregnancy, Psychological problems with miscarriage

Z30.0 General advice and advice on contraception

Safe sex, Intrauterine device contraception, Contraception, Contraceptive intrauterine, Oral contraception, Oral contraception during lactation and with estrogen contraindications, Postcoital contraception, Prevention of Pregnancy, Prevention of unwanted pregnancy, Emergency Contraception, Episodic prevention of pregnancy, Contraception in adolescents, Prevention of pregnancy (contraception)

Code CAS68-22-4

Pharmacology

The pharmacological action is gestagenic.

Inhibits the proliferative activity in hyperplastic endometrium, promotes secretory transformation reactions development of decidual stroma and atrophic changes of epithelial glands and stroma. Oppresses the secretion of gonadotropic hormones by the pituitary gland.

Well absorbed when taken orally. The time to reach Cmax is about 2 hours. In the liver, with the participation of enzymes of microsomal oxidation, biotransformation is exposed. T1 / 2 - 3-10 hours Excreted in the urine (up to 70% of the administered dose) and the intestine.

Application of Norethisterone

Premenstrual syndrome, mastodynia, mastopathy, dysmenorrhea with shortening secretory phase, dysfunctional uterine bleeding (with substitution purposes in failure corpus luteum hormone), tuberculosis, primary and secondary amenorrhea, cystic glandular hyperplasia of the endometrium, endometriosis, adenomyosis, uterine fibroids, infertility, miscarriage , Prevention and cessation of lactation, postponement of another menstruation, climacteric syndrome, contraception.

Contraindications

Hypersensitivity, breast cancer (including suspected) and sexual organs, the tendency to thrombosis, acute thrombophlebitis or thromboembolism, urinary tract bleeding of unknown origin, metrorrhagia unclear origin, bleeding from genitals of unclear origin, cholestatic jaundice of pregnant women (in m .ch. history), acute liver disease (including benign and malignant neoplasms) expressed hepatic dysfunction, hepatitis, cirrhosis, pregnancy (including suspected it, except Application for miscarriage), the period of puberty.

Restrictions for use

Bronchial asthma, chronic heart failure, epilepsy, hypertension, migraine, renal failure, convulsions, impaired central nervous system (including history), diabetes mellitus, liver disease (disorder), hyperlipidemia, thrombophlebitis a history of thromboembolism in Anamnesis.

Side effects

Nausea, vomiting, metrorrhagia, peripheral edema, fatigue, paresthesias, weight gain, breast tenderness, allergic reactions (rash, pruritus); With prolonged use - thrombosis, thromboembolism.

Interaction

Barbiturates reduce plasma concentrations (accelerate metabolism).

Routes of administration

Inside.

Precautions

Before the beginning of treatment it is necessary to clarify the cause of vaginal bleeding, confirm its functional character and exclude the presence of malignant neoplasm.